

RECEIVED  
CENTRAL FAX CENTER

Amendments to the Claims

AUG 23 2006

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (currently amended) - A ligand specific for human epithelial cancer cells, wherein said ligand has the chemical structure of  $cX_2GX_4GX_6X_7c$ , in which "c" is D-cysteine; " $X_2$ ", " $X_4$ ", " $X_6$ ", and " $X_7$ " are "X" is an amino acids selected from the group consisting of L-amino acids, D-amino acids, and unnatural amino acids; and "G" is glycine; and further, wherein " $X_2$ " is either polar and neutral or polar and acidic, and wherein " $X_4$ " is hydrophobic.
2. (original) - The ligand of claim 1, wherein said epithelial cells are ovarian cancer cells.
3. (currently amended) - A ligand specific for human non-epithelial cancer cells, wherein said ligand has the chemical structure of  $cX_2GX_4GX_6X_7c$ , in which "c" is D-cysteine; " $X_2$ ", " $X_4$ ", " $X_6$ ", and " $X_7$ " are amino acids selected from the group consisting of L-amino acids, D-amino acids, and unnatural amino acids; and "G" is glycine; and further, wherein " $X_2$ " is either polar and neutral or polar and acidic, and wherein " $X_4$ " is hydrophobic. "G" is glycine; " $X_2$ " is an amino acid selected from the group consisting of D,d,N, n, S,Q,q,T, HoSer, Cit, E, e, HoCit, Hyp, Aad, Lys(Ac), A, 4-Pal, D-3-Pal, Pra, D-Pra, Y, Aib, M, Phe(4-CN), Tyr(3-NO<sub>2</sub>), Tyr(Me), Phe(4-NO<sub>2</sub>), Bug, Ach, Tyr(3,5-I), Aic, Phe(3-Cl), Chg, Bta, Bpa, Phe(3,4-Cl), Hyp(Bzl), and Cha; and " $X_4$ ", " $X_6$ " and " $X_7$ " are amino acids selected from the group consisting of N, S, Q, T, HoSer, Cit, HoCit, Hyp, H, A, Pal, D-3-Pal, Pra, R, Y, Aib, Abu, P, M, V, Nva, Tyr(3-NO<sub>2</sub>), W, Phg, Phe(4-NO<sub>2</sub>), Bug, I, Ach, L, Nle, Phe(4-Me), Aic, Phe(3-Cl), HoPhe, Chg, Bta, Bpa, 2-Nal, 1-Nal, Phe(3,4-Cl), Hyp(Bzl), and Cha.
4. (original) - The ligand of claim 3, wherein said non-epithelial cells are brain cancer cells.
5. (canceled)
6. (canceled)

7. (canceled)
8. (canceled)
9. (canceled)
10. (new) - The ligand of claim 1, wherein said ligand has the chemical structure of cDGLGDDc.
11. (new) - A ligand specific for human epithelial cancer cells, wherein said ligand has the chemical structure of cX<sub>2</sub>GX<sub>4</sub>GX<sub>6</sub>X<sub>7</sub>c, in which "c" is D-cysteine, "G" is glycine; "X<sub>2</sub>" is an amino acid selected from the group consisting of D,d,N, n, S,Q,q,T, HoSer, Cit, E, e, HoCit, Hyp, Aad, Lys(Ac), A, 4-Pal, D-3-Pal, Pra, D-Pra, Y, Aib, M, Phe(4-CN), Tyr(3-NO<sub>2</sub>), Tyr(Me), Phe(4-NO<sub>2</sub>), Bug, Ach, Tyr(3,5-I), Aic, Phe(3-Cl), Chg, Bta, Bpa, Phe(3,4-Cl), Hyp(Bzl), and Cha; and "X<sub>4</sub>", "X<sub>6</sub>" and "X<sub>7</sub>" are amino acids selected from the group consisting of N, S, Q; T, HoSer, Cit, HoCit, Hyp, H, A, Pal, D-3-Pal, Pra, R, Y, Aib, Abu, P, M, V, Nva, Tyr(3-NO<sub>2</sub>), W, Phg, Phe(4-NO<sub>2</sub>), Bug, I, Ach, L, Nle, Phe(4-Me), Aic, Phe(3-Cl), HoPhe, Chg, Bta, Bpa, 2-Nal, 1-Nal, Phe(3,4-Cl), Hyp(Bzl), and Cha.
12. (new) - The ligand of claim 11, wherein said ligand has the chemical structure of c-d-G-HoCit-G-P-Q-c.
13. (new) - The ligand of claim 3, wherein said ligand has the chemical structure of cDGLGDDc.
14. (new) - The ligand of claim 3, wherein said ligand has the chemical structure of cDGWGPNC.